ImmunoCard STAT! EHEC is an immunochromatographic rapid test for the qualitative detection of Shiga toxins 1 and 2 (also called Verotoxins) produced by E. coli in cultures derived from clinical stool specimens. ImmunoCard STAT! EHEC is used in conjunction with the patient's clinical symptoms and other laboratory tests to aid in the diagnosis of diseases caused by enterohemorrhagic E. coli (EHEC) infections.

Device Description

ImmunoCard STAT! EHEC is an immunochromatographic rapid test utilizing monoclonal antibodies labeled with red-colored gold particles. The test device has a circular sample port and an oval-shaped test (Toxin 1, Toxin 2) and control (Control) window. The sample is applied to the chromatography paper via the circular sample port. The sample is absorbed through the pad to the reaction zone containing colloidal, gold-labeled antibodies specific to Shiga toxins. Any Shiga toxin (ST1 and ST2) antigen present complexes with the gold-labeled antibody and migrates through the pad until it encounters the binding zones in the test (Toxin 1, Toxin 2) area. The binding zones (Toxin 1 and Toxin 2) contain another anti-ST1 or -ST2 antibody, which immobilizes any Shiga toxin-antibody complex present. Due to the gold labeling, a distinct red line is then formed. The remainder of the sample continues to migrate to another binding reagent zone within the control zone, and also forms a further distinct red line (positive control). Regardless of whether any Shiga toxin is present or not, a distinct red line should always be formed in the control zone and confirms that the test is working correctly.

AI/ML Overview

Here's a summary of the acceptance criteria and study details for the ImmunoCard STAT! EHEC device, based on the provided text:

Acceptance Criteria and Device Performance

1. Table of Acceptance Criteria and Reported Device Performance

The acceptance criteria are implicitly derived from the comparative performance against the predicate device, Premier EHEC, and the Duopath Verotoxin GLISA, as well as the observed reproducibility. The document emphasizes "substantial equivalence" as the primary goal. The critical performance metrics are clinical sensitivity and specificity.

Performance Characteristic	Acceptance Criteria (Implied by Predicate/Study Goals)	ImmunoCard STAT! EHEC Performance (Combined Broths)
Clinical Sensitivity	Comparable to Premier EHEC (100% reported for predicate)	90.3% (post-resolution: 94.9%)
Clinical Specificity	Comparable to Premier EHEC (97.9% reported for predicate)	100% (post-resolution: 100.0%)
Reproducibility	100% (as shown by predicate)	100%
Correlation	Comparable to predicate (98.1%)	98.2% (post-resolution: 99.1%)

Note on Acceptance Criteria: The document does not explicitly state numerical acceptance criteria in a dedicated section. Instead, the "Substantial Equivalence" determination (K062546) is based on the performance of the new device being comparable to the predicate device and being safe and effective for its intended use. The predicate device's performance characteristics serve as the benchmark for "acceptable" performance. The post-resolution values for sensitivity and correlation are higher and demonstrate improved agreement with the gold standard.

2. Sample Size Used for the Test Set and Data Provenance

Test Set Sample Size: A total of 360 stool samples were evaluated (340 produced growth in GN broth, 344 in Mac broth).
Data Provenance: The data was collected from clinical samples in the United States, Canada, and Argentina. The study was prospective for collecting clinical samples to validate the product's new intended use with broth cultures. Some samples were tested fresh, while others were evaluated following frozen storage.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

The document does not specify the number or qualifications of experts used to establish the ground truth. It refers to the cytotoxin assay (CTA) as the method for resolving discrepant results, which implies a laboratory-based gold standard.

4. Adjudication Method for the Test Set

Adjudication Method: Discrepant results between the ImmunoCard STAT! EHEC and the predicate device (Premier EHEC) were further analyzed using a cytotoxin assay (CTA). This indicates an adjudication process where the CTA served as a tie-breaker or definitive test for discordant outcomes.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done

No, an MRMC comparative effectiveness study was not explicitly mentioned or described in the provided text. The device is a rapid immunochromatographic assay with clear positive/negative results (red lines), which typically does not involve human interpretation variability in the same way as imaging studies. The performance metrics focus on the device's accuracy against a reference standard.

6. If a Standalone Study Was Done

Yes, a standalone study was performed. The "Performance evaluation" section details the evaluation of ImmunoCard STAT! EHEC with clinical samples (broth cultures) and its performance (sensitivity, specificity) was measured independently and then compared to the predicate device.

7. The Type of Ground Truth Used

Primary Ground Truth: The predicate device (Premier EHEC) was initially used as the reference for comparison in calculating initial sensitivity and specificity. However, for resolving discrepant results, the cytotoxin assay (CTA) was used, which represents a more definitive diagnostic method for Shiga toxins. Therefore, the ground truth for discordant samples was cytotoxin assay (outcomes data/definitive lab test).

8. The Sample Size for the Training Set

The document does not specify a separate training set size. The study focuses on the performance evaluation of the ImmunoCard STAT! EHEC for its new intended use. Since this is an immunochromatographic assay, typically, extensive machine learning training sets in the modern sense are not applicable. The device's design and reagent selection would have been developed prior to this validation study.

9. How the Ground Truth for the Training Set Was Established

As no explicit training set is mentioned in the context of machine learning, this question is not applicable in the traditional sense. The "ground truth" for the device's development (e.g., antibody selection, assay parameters) would have been established through a combination of scientific knowledge, laboratory experiments with known positive and negative controls, and optimization trials, rather than a single "training set" with established ground truth from clinical samples.

Summary

{0}------------------------------------------------

K062546

SUMMARY OF SAFETY AND EFFECTIVENESS

IDENTIFICATION INFORMATION

FEB 1 4 2007

SUBMITTERS INFORMATION

This summary of 510(k) safety and effectiveness is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.20.

SUBMITTER'S NAME AND ADDRESS: Meridian Bioscience, Inc. 3471 River Hills Drive Cincinnati, OH 45244

PHONE NUMBER: (513) 271-3700

FAX NUMBER: (513) 272-5213

CONTACT PERSON: Susan Rolih Official correspondent

DATE SUMMARY PREPARED: August 29, 2006

TRADE NAME: ImmunoCard STAT! EHEC

COMMON NAME: E coli toxins detection test

CLASSIFICATION NAME: Escherichia coli serological reagents

REGULATION: 866.3255

INTENDED USES: ImmunoCard STAT! EHEC is an immunochromatographic rapid test for the qualitative detection of Shiga toxins 1 and 2 (also called Verotoxins) produced by E. coli in cultures derived from clinical stool specimens. ImmunoCard STAT! EHEC is used in conjunction with the patient's clinical symptoms and other laboratory tests to aid in the diagnosis of diseases caused by enterohemorrhagic E. coli (EHEC) infections.

PREDICATE DEVICE: Premier EHEC (K953362)

BACKGROUND: Among the E. coli human pathogens, Shiga toxin-producing strains of E. coli have gained in importance in recent years. The group of EHEC, with their highly pathogenic serovars 0157:H7. 026, 0103, 0111, 0145, and other strains are of particular concern. Production of Shiga toxins is the most common criteria for the detection of this group of bacteria. Shiga toxins can be classified into two main categories: Shiga toxin 1 (ST1) and Shiga toxin 2 (ST2). EHEC strains may produce ST1 or ST2 only or both ST1 and ST2 simultaneously. EHEC are capable of initiating life-threatening illnesses, particularly in young children, the elderly or patients with immune deficiency. The main sources of infection are contaminated, raw or insufficiently heated foods of animal origin, eg, meat and dairy products. The reservoir for EHEC is the feces of cattle. sheep and goats. These microorganisms can enter food during the processing of meat and dairy products if hygienic conditions are inadequate. The incidence of food infection caused by Shiga toxin-producing E. coli demands reliable and rapid methods of detection. In addition to traditional culture methods, immunological techniques are becoming more useful due to their improved specificity and sensitivity. ImmunoCard STAT! EHEC is an immunological screening test based on the lateral flow principle.

{1}------------------------------------------------

This product was previously cleared to market as Duopath Verotoxin GLISA (K031367) to identify Shiga toxin 1 or Shiga toxin 2-producing strains of E coli isolated from colonies derived from human stools cultured on Sorbitol MacConkey agar plates. This application adds now intended use to the device (use with broth cultures inoculated with human stool) and changes the name of the product.

Type of test

Qualitative, rapid, single use, immunochromatographic assay

Specimen type

Human stool samples inoculated into enrichment media (GN or Mac broth) (This application.)

Conditions for use

ImmunoCard STAT! EHEC is designed for use by laboratory professionals under normal environmental conditions. The assay, which is stored at 2-8 C when not in use, is brought to room temperature (20-25 C) before use. Normal laboratory lighting, humidity and temperature do not affect the performance of the assay.

Contraindications

There are no contraindications associated with the use of this product.

Special instrument requirements

No instruments are used with this device.

Combination with other medical devices

No other medical devices are used in combination with this device.

{2}------------------------------------------------

able 1. Comparison of ImmunoCard STAT! EHEC to the predicate device and its prior design

: 1

Characteristics	ImmunoCard STAT! EHEC	Premier EHEC (predicate)	Duopath Verotoxin GLISA (predicate)
Device Type
Technology	Single use, rapid, lateral flow immunoassay	Microwell-based enzyme-linked immunoassay	Single use, rapid, lateral flow immunoassay
In vitro diagnostic device	Yes	Yes	Yes
Control	Includes external control reagent	Includes external control reagent	No control reagent included
Calibrator	No	No	No
Assay Features
Human factors	No special equipment	EIA-related equipment	No special equipment
Sterile device	No	No	No
Mechanical safety	Not applicable	Not applicable	Not applicable
Environmental safety	Normal medical waste	Normal medical waste	Normal medical waste
Chemical hazards	None	None	None
Radiation safety	Not applicable	Not applicable	Not applicable
Intended Use
Detection of Shiga toxins 1 and 2	Yes	Yes	Yes
Differentiation between Shiga toxins 1 and 2	Yes	No	Yes
Screening test	Yes	Yes	Yes
Diagnostic test	No	No	No
Identification test	Yes	No	Yes
Monitoring therapy	No	No	No

. ·

. .

ਂ

1.000 1.00

: 上

This Table is continued on the next page.

Page 3 of 12

and the comments of the comments

Section 5

{3}------------------------------------------------

led.




continu







T





able
L
•

ble Samples	ImmunoCard STAT! EHEC	Premier EHEC(predicate)	Duopath Verotoxin GLISA
Droth culture	Yes	Yes	No
agar culture	Yes	No	Yes
stool	No	Yes	No
s/Components
Medium	Test Device with nitrocellulose strip	Antibody-coated microwell	Test Device with nitrocellulose strip
gate Reagent	In Test Device	Stand alone reagent	In Test Device
Diluent/Negative	Yes	Yes	Yes
e
ol (external)	No	Yes	No
rate Reagent	No	Yes	No
Solution	Yes	No	Yes
al positive run control	Yes	No	Yes
al negative run control	Yes	Yes	No
al positive control	Yes	Yes	No
of/Antibodies
re ST1 antibodies	Murine monoclonal	Murine monoclonal	Murine monoclonal
re ST2 antibodies	Murine monoclonal	Murine monoclonal	Murine monoclonal
cor ST1 Antbodies	Murine monoclonal	Rabbit polyclonal	Murine monoclonal
cor ST2 Antibodies	Murine monoclonal	Rabbit polyclonal	Murine monoclonal
e Control	Inactivated toxin	Inactivated toxin	None
ison of assay steps*	None	EIA-related	None
oment Required	Moderately complex	Moderately complex	Moderately complex
I of skill required	5	15	5
y steps	Pink-red band	Yellow color	Pink-red band
point		OD > 0.150 (dual wavelength)	Pos = color band Neg = no color

: 上

: :

This Table is continued on the next page.

Page 4 of 12

Section 5

{4}------------------------------------------------

Table 1 continued

Performance Characteristics	ImmunoCard STAT! EHEC	Premier EHEC (predicate)	Duopath Verotoxin GLISA
Clinical Sensitivity	90.3%	100%	Not calculated
Clinical Specificity	100%	97.9%	Not calculated
Precision/Reproducibility (intra-assay)	100%	100%	100%
Linearity/reportable range	N/A	N/A	N/A
Analytical limit	ST1 = 25 ug/mL	ST1 = 7 pg/well	N/A
Detection/sensitivity	ST2 = 25 ug/mL	ST2 = 15 pg/well	ST1 and ST2 = one colony per enrichment broth
Assay cutoff	N/A	OD 0.150 (dual wavelength)	N/A
Indeterminant range	N/A	N/A	N/A

. . . . . .

1 12

. · ·

{5}------------------------------------------------

DEVICE DESCRIPTION AND TECHNOLOGICAL PRINCIPLES

Construct

Each ImmunoCard STAT! EHEC test kit contains three reagents/components.

1. Test Devices, in individual foil pouches with desiccants.
1. Sample Diluent (Negative Control) in a plastic dropper vial
1. Positive Control in a plastic dropper vial

Calibrators

No calibrators are needed for this device.

Controls

This assay includes an internal control line that is used to demonstrate that the broth samples have been applied, that it has flowed correctly, and that the conjugated detector antibodies are active at the time of use. A colorless to faint pink background around the Toxin 1 and 2 Test Lines serves as a negative control and indicates the reagents were performing correctly at the time of testing.

The Positive Control external control reagent is used with the Sample Diluent/Negative Control when external control testing is warranted. The readents also serve as indicators that the test was performed correctly, that reagents were active and specific at the time of use, and that the Test Device membrane supports proper sample flow.

Failure of the internal and external controls to produce the expected results suggests the test was not performed correctly.

Technological principles

ImmunoCard STAT! EHEC is an immunochromatographic rapid test utilizing monoclonal antibodies labeled with red-colored gold particles. The test device has a circular sample port and an oval-shaped test (Toxin 1, Toxin 2) and control (Control) window.
1. The sample is applied to the chromatography paper via the circular sample port (Sample).
1. The sample is absorbed through the pad to the reaction zone containing colloidal, gold-labeled antibodies specific to Shiga toxins.
3.Any Shiga toxin (ST1 and ST2) antigen present complexes with the gold-labeled antibody and migrates through the pad until it encounters the binding zones in the test (Toxin 1, Toxin 2) area.
4.The binding zones (Toxin 1 and Toxin 2) contain another anti-ST1 or -ST2 antibody, which immobilizes any Shiga toxin-antibody comblex present. Due to the gold labeling, a distinct red line is then formed.
5.The remainder of the sample continues to migrate to another binding reagent zone within the control zone, and also forms a further distinct red line (positive control). Regardless of whether any Shiga toxin is present or not, a distinct red line should always be formed in the control zone and confirms that the test is working correctly.

CLINICAL TRIAL DATA

Performance evaluation

ImmunoCard STAT! EHEC is a modification of Duopath Verotoxin GLISA (K031367), cleared to market to detect EHEC in stool samples that had been cultured on Sorbitol MacConkey plates. This premarket submission describes the evaluations performed with clinical samples to validate the product's new intended use with broth cultures inoculated with human stool.

This study was conducted with samples tested fresh or following frozen storage. Samples were collected in the United States, Canada and Argentina. A total of 360 stool samples were evaluated in either GN, MacConkey (Mac) broths or both. 340 of these samples produced growth in GN broth, while 344 produced growth in Mac broth. Table 2 identifies the ages of the patients from whom samples were collected during the study. Table 3 provides the gender of each patient. Table 4 summarizes the sensitivity obtained with GN and Mac stool broth samples. Samples producing discrepant results between Premier EHEC and ImmunoCard

{6}------------------------------------------------

	Specimen Type
GN Samples	Male	Female	Not defined
Clinical site 3
Total tested	37	51	213
Mean positive reaction strength	2.0	3.1	3.5
Positive reaction range	0.5-8.0	0.5-6.0	0.5-8.0
Clinical site 4
Total tested	14	25	0
Mean positive reaction strength	1.0	All Negative	N/A
Positive reaction range	0.5-5.0	All Negative	N/A
Clinical site Totals
Total tested	51	76	213
Mean positive reaction strength	1.9	3.1	3.5
Positive reaction range	0.5-5.0	0.5-6.0	0.5-8.0
MAC Samples	Male	Female	Not defined
Clinical site 3
Total tested	40	52	213
Mean positive reaction strength	2.8	3.3	3.3
Positive reaction range	0.5-7.0	0.5-7.0	0.5-6.0
Clinical site 4
Total tested	14	25	0
Mean positive reaction strength	3.0	All Negative	N/A
Positive reaction range	3.0	All Negative	N/A
Clinical site Totals
Total tested	54	77	213
Mean positive reaction strength	2.9	3.3	3.3
Positive reaction range	0.5-7.0	0.5-7.0	0.5-6.0

Table 3 Classification of patients from whom samples were collected based on gender.

{7}------------------------------------------------

STAT! EHEC were further analyzed using cytotoxin assay (Table 5). These samples generally produced weak reactions (less than 0.300) in Premier EHEC (Table 6). Some of the samples grew in MAC broth but not GN broth.

Patient exclusion criteria

There are no patient exclusion criteria associated with ImmunoCard STAT! EHEC.

Influence of other disease states

There is no influence by other disease states on test results.

Table 2. Categories of patients by age from whom samples were collected for clinical studies

Patient Age and Sample Storage GN Samples	birth to 1month	>1 month to2 years	>2 years to12 years	>12 years to21 years	>21 years	Not Defined
Clinical site 3
Total tested	1	4	12	10	62	213
Mean positive reaction strength	All Negative	All Negative	3.6	2.6	2.4	3.5
Positive reaction range	All Negative	All Negative	1.0-5.0	0.5-6.0	0.5-6.0	0.5-8.0
Clinical site 4
Total tested	N/A	1	N/A	2	35	0
Mean positive reaction strength	N/A	All Negative	N/A	All Negative	1.0	N/A
Positive reaction range	N/A	All Negative	N/A	All Negative	1.0	N/A
Clinical site Totals
Total tested	1	5	12	12	97	213
Mean positive reaction strength	All Negative	All Negative	3.6	2.6	2.3	All Negative
Positive reaction range	All Negative	All Negative	1.0-5.0	0.5-6.0	0.5-6.0	All Negative
Patient Age and Sample Storage MAC Samples	birth to 1month	>1 month to2 years	>2 years to12 years	>12 years to21 years	>21 years	Not Defined
Clinical site 3
Total tested	1	5	13	10	63	213
Mean positive reaction strength	All Negative	All Negative	3.9	2.6	3.1	3.3
Positive reaction range	All Negative	All Negative	0.5-6.0	0.5-7.0	0.5-7.0	0.5-6.0
Clinical site 4
Total tested	N/A	1	N/A	2	36	0
Mean positive reaction strength	N/A	All Negative	N/A	All Negative	3.0	N/A
Positive reaction range	N/A	All Negative	N/A	All Negative	3.0	N/A
Clinical site Totals
Total tested	1	6	13	12	99	213
Mean positive reaction strength	All Negative	All Negative	3.9	2.6	3.0	3.3

All Negative

0.5 - 6.0

0.5 - 7.0

Positive reaction range

0.5 · 7.0

0.5 - 6.0

{8}------------------------------------------------

Table 6. Analysis of samples producing discrepant results

Site	SpecimenSerial#	Specimen Storage	ICS EHECResult	PremierAbsorbance	Premier Interp	CTA Result
3	2831	Cary-Blair 2-8 C	Negative	0.223	Positive	Negative
3	282	Unpreserved --70 C	Negative	0.289	Positive	Cytotoxin Positive
3	281	Unpreserved -70 C	Negative	0.387	Positive	Negative
3	280	Unpreserved -70 C	Negative	0.151	Positive	Negative
3	269	Unpreserved -70 C	Negative	0.535	Positive	Cytotoxin Positive
3	266	Unpreserved -70 C	Negative	0.159	Positive	Negative
3	289	Unpreserved -70 C	Negative	0.280	Positive	Negative

GN broth-enriched samples

Mac broth-enriched samples

Site	Specimen Serial #	Specimen Storage	ICS EHEC Result	Premier Absorbance	Premier Interp	CTA Result
3	2831	Cary-Blair 2-8 C	Negative	0.314	Positive	Cytotoxin Positive
3	282	Unpreserved -70 C	Negative	0.174	Positive	Negative
3	281	Unpreserved -70 C	Negative	0.239	Positive	Cytotoxin Positive
3	280	Unpreserved -70 C	Negative	0.355	Positive	Cytotoxin Positive
3	110	Unpreserved -70 C	Negative	0.157	Positive	Negative

Legend: CTA = cytotoxin assay

{9}------------------------------------------------

able 4 Clinical sensitivity and specificity tabl

GN Broth Enrichment CulturesPremier EHEC				MacConkey Broth Enrichment CulturesPremier EHEC
ICS EHEC GN	Positive	Negative	Total	ICS EHEC MAC	Positive	Negative	Total
Positive	54	0	54	Positive	58	0	58
Negative	7	279	286	Negative	5	281	281
Total	61	279	340	Total	63	281	344
Sensitivity	54/61	88.5%	77.8%-95.3%	Sensitivity	58/63	92.1%	82.4%
Specificity	279/279	100.0%	98.7%-100%	Specificity	281/281	100.0%	98.7%
PPV	54/54	100.0%	93.4%-100%	PPV	58/58	100.0%	93.8%
NPV	279/286	97.6%	95.0%-99.0%	NPV	281/286	98.3%	96.0%
Correlation	333/340	97.9%	95.8%-99.2%	Correlation	339/344	98.5%	96.6%

ombined Broth Total

Total

..............................................................................................................................................................................

	Premier EHEC
ICS EHECTotal	Positive	Negative	Total
Positive	112	0	112
Negative	12	560	572
Total	124	560	684
Sensitivity	112/124	90.3%	83.7% - 94.9%
Specificity	560/560	100.0%	99.3% - 100%
PPV	112/112	100.0%	96.8% - 100%
NPV	560/572	97.9%	96.4% - 98.9%
Correlation	672/684	98.2%	97.0% - 99.1%

82.4% - 97.4%

286 344

98.7% - 100% 93.8% - 100%

96.0% - 99.4% 96.6% - 99.5%

ble 5 Test Data following resolution of discrepant samples by cytotoxin assa

GN Broth Enrichment Cultures				MacConkey Broth Enrichment
ICS EHEC GN	Premier EHEC Positive	Negative	Total	ICS EHEC MAC	Premier Positive
Positive	54	0	54	Positive	58
Negative	2	284	286	Negative	4
Total	56	284	340	Total	62
Sensitivity	54/56	96.4%	87.7%-99.6%	Sensitivity	58/62
Specificity	284/284	100.0%	98.7%-100%	Specificity	282/282
PPV	54/54	100.0%	93.4%-100%	PPV	58/58
NPV	284/286	99.3%	97.5%-99.9%	NPV	282/286
Correlation	338/340	99.4%	97.9%-99.9%	Correlation	340/344

An-an experience of the results

Total

Negative

richment Cultures
TEHEC

	Premier	EHEC
ICS EHECTotal	Positive	Negative	Total
Positive	112	0	112
Negative	6	566	572
Total	118	566	684
Sensitivity	112/118	94.9%	89.3% - 98.1%
Specificity	566/566	100.0%	99.4% - 100%
PPV	112/112	100.0%	96.8% - 100%
NPV	566/572	99.0%	97.7% - 99.6%
Correlation	678/684	99.1%	98.1% - 99.7%

84.3% - 98.2%

93.5%

286 344

282 282

98.7% - 100% 93.8% - 100%

100.0% 100.0%

96.5% - 99.6%
97.1% - 99.7%

98.8%

98.6%

{10}------------------------------------------------

EPRODUCIBILIT

ses precion. Inte-assay wabiliy vere assessed with reference panel more nouled will 51 am ST
if to 1 same in the epoded as her bother promose on a som polition in esay prese

able 7 Results of reproducibility evaluatio

Sample ID	SampleQual.Result	Site 3						Site 4
		Day 1Run 1	Day 1Run 2	Day 2Run 1	Day 2Run 2	Day 3Run 1	Day 3Run 2	Day 1Run 1	Day 1Run 2	Day 2Run 1	Day 2Run 2	Day 3Run 1	Day 3Run 2
1 HP ST1	7	7.0	7.0	7.0	7.0	7.0	7.0	7.0	7.0	8.0	8.0	7.0	6.0
2 HP ST2	7	7.0	7.0	7.0	7.0	7.0	7.0	7.0	8.0	8.0	6.0	7.0	7.0
3 Cut off LP ST1	3	2.0	2.5	2.0	3.0	2.5	2.0	1.0	1.0	2.0	1.0	1.0	1.0
4 Cut off LP ST1	3	3.0	3.0	2.5	2.5	2.5	2.0	1.0	1.0	1.0	1.0	2.0	1.0
5 Cut off LP ST2	3	2.5	2.5	2.0	2.0	2.5	3.0	1.0	1.0	1.0	1.0	2.0	2.0
6 Cut off LP ST2	3	3.0	2.5	3.0	3.0	2.5	3.0	1.0	1.0	2.0	1.0	1.0	1.0
7 Cut off HN ST1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
8 Cut off HN ST1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
9 Cut off HN ST2	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10 Cut off HN ST2	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
11 LN	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Average highnegative value		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Average low positivevalue		2.6	2.6	2.4	2.6	2.5	2.5	1.0	1.0	1.5	1.3	1.5	1.3
Percent Correlation		100%						100%
Correlation of cut offSpecimens		Site 3100%						Site 4100%
Precision		Site 3100%						Site 4100%

{11}------------------------------------------------

Meridian Bioscience, Inc. Cincinnati, OH

510(k) application ImmunoCard STAT! EHEC

.. . . . .

Comparison to predicate

The following table compares the outcomes of trials using ImmunoCard STAT! EHEC to the data published for the predicate device, Premier EHEC.

Table 8 Comparison of the clinical performance of ImmunoCard STAT! to Premier EHEC

Performance Characteristics in Direct Comparison toClinical Status or Condition(Combined Samples)	ImmunoCard STAT!EHECCombined broths	Premier EHEC(predicate)Combined broths
Clinical Sensitivity	90.3%	100%
Clinical Specificity	100%	97.9%
Predictive Value of a Positive Test	100%	Not done
Predictive Value of a Negative Test	97.9%	Not done
Correlation	98.2%	98.1%
Performance characteristics
Precision/Reproducibility	100%	100%
Linearity/reportable range	N/A	N/A
Limit of detection	ST1 = 1.25 ng/mLST2 = 1.25 ng/mL	ST1 = 7 pg/wellST2 = 15 pg/well
Assay cutoff	N/A	OD 0.150 (dualwavelength

CONCLUSIONS

IlmmunoCard STAT! EHEC can be used to detect Shiga-toxin forming strains of E. coli in human stool samples. The performance of this device for the stool broth intended use is substantially equivalent to the predicate Premier EHEC

{12}------------------------------------------------

DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/12/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle with three tail feathers, representing the department's three main goals: protecting the health of all Americans, providing essential human services, and strengthening the nation's health and well-being. The eagle is surrounded by the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" in a circular arrangement.

Public Health Service

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

Ms. Susan Rolih Official Correspondent Meridian Bioscience, Inc. 3474 River Hills Drive Cincinnati, OH 45244

FEB 1 4 2007

Re: K062546 Trade/Device Name: ImmunoCardSTAT! EHEC Regulation Number: 21 CFR 866.3255 Regulation Name: Escherichia coli serological reagents Regulatory Class: Class I Product Code: GMZ Dated: February 6, 2007 Received: February 6, 2007

Dear Ms. Rolih:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

{13}------------------------------------------------

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240)276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

Sally, artur

Sally A. Hojvat, M.Sc., Ph.D. Director Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

{14}------------------------------------------------

ImmunoCard STAT! EHEC

510(k) Notification Meridian Bioscience, Inc.

INDICATIONS FOR USE STATEMENT ImmunoCard STAT! EHEC

510(K) Number: K062544

ImmunoCard STAT! EHEC is an immunochromatographic rapid test for the qualitative detection of Shiga toxins 1 and 2 (also called Verotoxins) produced by E. coli in cultures derived from dinical stool specimens. ImmunoCard STAT! EHEC is used in conjunction with the patient's clinical symptoms and other laboratory tests to aid in the diagnosis of diseases caused by enterchemorrhagic E. coli (EHEC) infections.

Prescription Use × (Part 21 CFR 801 Subpart D) AND/OR

Over-The-Counter Use (21 CFR 807 Subpart C)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Fuddie M. Poole
Division Sign-Off

Office of In Vitro Diagnostic Device Evaluation and Safety

576/k) KO62546

Regulation Number and Section

§ 866.3255

Escherichia coli serological reagents.(a)
Identification. Escherichia coli serological reagents are devices that consist of antigens and antisera used in serological tests to identifyEscherichia coli from cultured isolates derived from clinical specimens. Additionally, some of these reagents consist ofEscherichia coli antisera conjugated with a fluorescent dye used to identifyEscherichia coli directly from clinical specimens or cultured isolates derived from clinical specimens. The identification aids in the diagnosis of diseases caused by this bacterium belonging to the genusEscherichia, and provides epidemiological information on diseases caused by this microorganism. AlthoughEscherichia coli constitutes the greater part of the microorganisms found in the intestinal tract in humans and is usually nonpathogenic, those strains which are pathogenic may cause urinary tract infections or epidemic diarrheal disease, especially in children.(b)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 866.9.